Diclazuril, an anticoccidial agent, was developed for the prevention and treatment of protozoal infections, particularly coccidiosis in animals. Its history is marked by its high efficacy against intracellular stages of coccidia, helping to control infection in livestock and poultry, while exhibiting low toxicity to the host. Diclazuril is included in several veterinary combination therapies and feed additives to enhance protection against coccidial outbreaks. Its development involved extensive preclinical and field studies to optimize dosing, safety, and efficacy, making it a key component in integrated parasite management programsin animal husbandry.
BRAND NAMES
Clinacox – primarily used in poultry for prevention and treatment of coccidiosis.
Vecoxan – used in livestock, including cattle and sheep, for coccidial control.
Baycox-D – feed additive or oral drench for prophylactic use in animals.
MECHANISM OF ACTION
Diclazuril acts as a coccidiostat by selectively targeting the protozoal parasite’s apicoplast and mitochondrial function. It inhibits nuclear division and disrupts energy metabolism in intracellular stages of coccidia, preventing replication and development of oocysts. This leads to arrested parasite growth and eventual clearance of infection from the host.
PHARMACOKINETICS
Absorption
Diclazuril is poorly absorbed from the gastrointestinal tract, which is advantageous for its action against intestinal coccidia. When administered orally, only a small fraction reaches systemic circulation, allowing the drug to remain concentrated in the gut where protozoal parasites reside.
Distribution
Diclazuril has a very low volume of distribution due to its poor systemic absorption and primary localization in the gastrointestinal tract. Most of the administered dose remains in the intestinal lumen, where it exerts its antiparasitic effect.
Metabolism
Diclazuril undergoes minimal metabolism due to its limited systemic absorption. The small fraction that is absorbed may be slowly metabolized in the liver, but detailed metabolic pathways are not well characterized. Most of the administered drug remains unchanged in the gastrointestinal tract, allowing it to exert its local anticoccidial effect.
Elimination
Diclazuril is primarily eliminated unchanged via feces, reflecting its poor systemic absorption and predominant activity in the gastrointestinal tract. Only a minor portion may be excreted via urine if absorbed systemically.
PHARMACODYNAMICS
Diclazuril exerts its pharmacodynamic effect by inhibiting the intracellular development of coccidia, particularly in the intestinal epithelium of infected animals. It prevents nuclear division and disrupts energy metabolism in protozoal cells, leading to arrested growth and death of the parasites. Its effect is concentration-dependent, with higher intestinal concentrations providing stronger antiparasitic activity.
ADMINISTRATION
Diclazuril is administered orally, usually as a feed additive, water-soluble premix, or oral drench, depending on the target animal species and the purpose (prophylaxis or treatment). For poultry and livestock, it is incorporated into feed or drinking water at specified concentrations to ensure effective intestinal exposure.
DOSAGE AND STRENGTH
Diclazuril is typically formulated as a 0.5% to 1% feed premix or oral suspension, depending on the species and purpose of use. For poultry, the recommended prophylactic dose is usually 1 mg/kg of body weight per day, administered via feed or water during periods of high coccidial risk.
DRUG INTERACTIONS
Diclazuril exhibits minimal systemic absorption, so clinically significant drug interactions are rare. However, when used concurrently with other anticoccidial or antiparasitic agents, care should be taken to avoid additive toxicity or antagonistic effects.
FOOD INTERACTIONS
Diclazuril is administered orally in feed or water, and its absorption and efficacy can be influenced by feed composition. High levels of fat, fiber, or certain minerals in feed may slightly alter its intestinal availability, but these effects are generally not clinically significant due to its targeted local action in the gut.
CONTRAINDICATIONS
Diclazuril is contraindicated in animals with a known hypersensitivity to the drug or its formulation components. It should not be used in very young or unweaned animals unless specifically recommended by a veterinarian, as safety data may be limited in these populations. Use is also contraindicated in animals with severe gastrointestinal disorders that could alter drug delivery or absorption.
SIDE EFFECTS
Mild gastrointestinal upset
Reduced feed intake in sensitive animals
Transient lethargy or decreased activity
Local irritation if administered orally as a drench
Rare hypersensitivity reactions.
OVER DOSAGE
Overdosage of diclazuril is rarely associated with serious toxicity due to its low systemic absorption. Excessive doses may lead to mild gastrointestinal disturbances, such as diarrhea, reduced feed intake, or temporary lethargy. In severe cases, especially in young or sensitive animals, transient effects on liver enzymes or kidney function may occur, but these are uncommon.
TOXICITY
Diclazuril demonstrates low toxicity due to its poor systemic absorption and targeted activity in the gastrointestinal tract. Adverse effects are generally mild and localized, such as temporary diarrhea, reduced feed intake, or mild lethargy in sensitive animals. Severe toxic effects are rare, even at doses several times higher than recommended. Its wide safety margin makes diclazuril suitable for use in livestock and poultry, including during prophylactic regimens, with minimal risk of systemic organ toxicity.
